Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hyperlipoproteinemias

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 29 articles:
HTML format
Text format



Single Articles


    August 2019
  1. WITZTUM JL, Gaudet D, Freedman SD, Alexander VJ, et al
    Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
    N Engl J Med. 2019;381:531-542.
    PubMed     Text format     Abstract available


    April 2019
  2. BHATT DL, Steg PG, Miller M
    Cardiovascular Risk Reduction with Icosapent Ethyl. Reply.
    N Engl J Med. 2019;380:1678.
    PubMed     Text format    


  3. BORGHI C, Fogacci F, Cicero AFG
    Cardiovascular Risk Reduction with Icosapent Ethyl.
    N Engl J Med. 2019;380:1678.
    PubMed     Text format    


  4. CHAN LN
    Cardiovascular Risk Reduction with Icosapent Ethyl.
    N Engl J Med. 2019;380:1677.
    PubMed     Text format    


    March 2019
  5. FERENCE BA, Ray KK, Catapano AL, Ference TB, et al
    Mendelian Randomization Study of ACLY and Cardiovascular Disease.
    N Engl J Med. 2019;380:1033-1042.
    PubMed     Text format     Abstract available


  6. RAY KK, Bays HE, Catapano AL, Lalwani ND, et al
    Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
    N Engl J Med. 2019;380:1022-1032.
    PubMed     Text format     Abstract available


    January 2019
  7. KASTELEIN JJP, Stroes ESG
    FISHing for the Miracle of Eicosapentaenoic Acid.
    N Engl J Med. 2019;380:89-90.
    PubMed     Text format    


    November 2018
  8. BHATT DL, Steg PG, Miller M, Brinton EA, et al
    Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812792.
    PubMed     Text format     Abstract available


  9. SCHWARTZ GG, Steg PG, Szarek M, Bhatt DL, et al
    Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
    N Engl J Med. 2018 Nov 7. doi: 10.1056/NEJMoa1801174.
    PubMed     Text format     Abstract available


    August 2018
  10. RAWSHANI A, Rawshani A, Franzen S, Sattar N, et al
    Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2018;379:633-644.
    PubMed     Text format     Abstract available


    May 2018
  11. KOEHLER VF, Parhofer KG
    Xanthoma Striatum Palmare.
    N Engl J Med. 2018;378:e26.
    PubMed     Text format    


    November 2017
  12. CALABRO P, Gragnano F, Pirro M
    Cognitive Function in a Randomized Trial of Evolocumab.
    N Engl J Med. 2017;377:1996-7.
    PubMed     Text format    


  13. GIUGLIANO RP, Sabatine MS, Ott BR
    Cognitive Function in a Randomized Trial of Evolocumab.
    N Engl J Med. 2017;377:1997.
    PubMed     Text format    


    August 2017
  14. POONIA A, Giridhara P
    Xanthomas in Familial Hypercholesterolemia.
    N Engl J Med. 2017;377:e7.
    PubMed     Text format    


    July 2017
  15. GAUDET D, Gipe DA, Pordy R, Ahmad Z, et al
    ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2017;377:296-297.
    PubMed     Text format    


    April 2017
  16. RIDKER PM, Tardif JC, Amarenco P, Duggan W, et al
    Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
    N Engl J Med. 2017;376:1517-1526.
    PubMed     Text format     Abstract available


  17. BEIGNEUX AP, Miyashita K, Ploug M, Blom DJ, et al
    Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.
    N Engl J Med. 2017 Apr 5. doi: 10.1056/NEJMoa1611930.
    PubMed     Text format     Abstract available


    March 2017
  18. RAY KK, Landmesser U, Leiter LA, Kallend D, et al
    Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
    N Engl J Med. 2017 Mar 17. doi: 10.1056/NEJMoa1615758.
    PubMed     Text format     Abstract available


  19. RIDKER PM, Revkin J, Amarenco P, Brunell R, et al
    Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
    N Engl J Med. 2017 Mar 17. doi: 10.1056/NEJMoa1701488.
    PubMed     Text format     Abstract available


  20. SABATINE MS, Giugliano RP, Keech AC, Honarpour N, et al
    Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
    N Engl J Med. 2017 Mar 17. doi: 10.1056/NEJMoa1615664.
    PubMed     Text format     Abstract available


    February 2017
  21. KHERA AV, Kathiresan S
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498-9.
    PubMed     Text format    


  22. MARTIN AC, Watts GF
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498.
    PubMed     Text format    


  23. KULLO IJ, Safarova MS
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498.
    PubMed     Text format    


  24. HINGORANI AD, Futema M, Humphries S
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:499.
    PubMed     Text format    



  25. Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498-500.
    PubMed     Text format    


    January 2017
  26. SCHULMAN AR, Vaidya A, Tavakkoli A, Jajoo K, et al
    Making the Connection.
    N Engl J Med. 2017;376:e5.
    PubMed     Text format    


    October 2016
  27. MCCRINDLE BW, Gidding SS
    What Should Be the Screening Strategy for Familial Hypercholesterolemia?
    N Engl J Med. 2016;375:1685-1686.
    PubMed     Text format    


  28. WALD DS, Bestwick JP, Morris JK, Whyte K, et al
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2016;375:1628-1637.
    PubMed     Text format     Abstract available


    September 2016
  29. LAMPSON BL, Gray SW, Cibas ES, Levy BD, et al
    CLINICAL PROBLEM-SOLVING. Tip of the Tongue.
    N Engl J Med. 2016;375:880-6.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: